Damora Therapeutics, Inc. (DMRA)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
29.00 USD
-1.60
(-5.229%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 29.00 |
Hot Take ↕ | Aug. 22, 2026, 3:56 a.m. EDT
The investment case here is structurally broken. Over the last four years, the stock has erased nearly 97% of its value, with every single year showing a double-digit decline, including a catastrophic 76% drop last year. This is not a temporary correction; it is a multi-year structural deterioration where the market has repeatedly rejected the business model. While analysts are currently shouting 'strong buy' and the price has recently bounced off multi-year lows, these are classic signs of a distressed asset trading at a discount to a potential turnaround, not a sign of a healthy company returning to growth. The fundamentals confirm the despair: negative earnings, massive losses, and a balance sheet that is burning through cash without a proven path to profitability. There is no dividend to provide income, and the recent price action is merely a relief rally in a dying trend. Until there is concrete evidence of a successful clinical trial or a sustainable revenue engine, this remains a speculative gamble on a resurrection, not a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.229060 |
| MSTL | 0.261763 |
| AutoETS | 0.277106 |
| AutoARIMA | 0.277545 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 0.97 |
| Ljung-Box p | 0.006 |
| Jarque-Bera p | 0.196 |
| Excess Kurtosis | 1.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 1,790,330,112 |
| Forward P/E | -13.54 |
| Beta | 1.48 |
| Previous Name | Galecto, Inc. |
| Website | https://www.damoratx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 9.2 |
| Address1 | Building 23 |
| Address2 | Suite 105 221 Crescent Street |
| All Time High | 449.75 |
| All Time Low | 2.01 |
| Ask | 36.68 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 286,490 |
| Average Daily Volume3 Month | 569,098 |
| Average Volume | 569,098 |
| Average Volume10Days | 286,490 |
| Beta | 1.48 |
| Bid | 21.68 |
| Bid Size | 2 |
| Book Value | 6.254 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 29.0 |
| Current Ratio | 19.731 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 30.71 |
| Day Low | 28.415 |
| Display Name | Damora Therapeutics |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -96,325,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.325 |
| Enterprise Value | 1,379,812,096 |
| Eps Current Year | -1.8925 |
| Eps Forward | -2.1425 |
| Eps Trailing Twelve Months | -0.26 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 28.8921 |
| Fifty Day Average Change | 0.10790062 |
| Fifty Day Average Change Percent | 0.0037346063 |
| Fifty Two Week Change Percent | 920.0 |
| Fifty Two Week High | 38.325 |
| Fifty Two Week High Change | -9.325001 |
| Fifty Two Week High Change Percent | -0.24331377 |
| Fifty Two Week Low | 2.45 |
| Fifty Two Week Low Change | 26.55 |
| Fifty Two Week Low Change Percent | 10.836734 |
| Fifty Two Week Range | 2.45 - 38.325 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,603,978,200,000 |
| Float Shares | 41,399,222 |
| Forward Eps | -2.1425 |
| Forward P E | -13.53559 |
| Free Cashflow | -15,979,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Fullday Change | -1.6 |
| Fullday Change Percent | -5.22876 |
| Fullday Price | 29.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.076 |
| Held Percent Institutions | 1.05691 |
| Implied Shares Outstanding | 61,735,519 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,976,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts. |
| Long Name | Damora Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,790,330,112 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_154090027 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -241,250,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,897,132,498 |
| Number Of Analyst Opinions | 9 |
| Open | 30.38 |
| Operating Cashflow | -44,515,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 781 281 9020 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 29.0 |
| Post Market Time | 1,787,959,804 |
| Prev Name | Galecto, Inc. |
| Previous Close | 30.6 |
| Price Eps Current Year | -15.323646 |
| Price Hint | 2 |
| Price To Book | 4.637032 |
| Profit Margins | 0.0 |
| Quick Ratio | 19.651 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1 |
| Region | US |
| Regular Market Change | -1.6 |
| Regular Market Change Percent | -5.22876 |
| Regular Market Day High | 30.71 |
| Regular Market Day Low | 28.415 |
| Regular Market Day Range | 28.415 - 30.71 |
| Regular Market Open | 30.38 |
| Regular Market Previous Close | 30.6 |
| Regular Market Price | 29.0 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 371,723 |
| Return On Assets | -0.21609 |
| Return On Equity | -0.99741995 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 61,735,519 |
| Shares Percent Shares Out | 0.076799996 |
| Shares Short | 4,739,939 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,688,241 |
| Short Name | Damora Therapeutics, Inc. |
| Short Percent Of Float | 0.0896 |
| Short Ratio | 11.63 |
| Source Interval | 15 |
| State | MA |
| Symbol | DMRA |
| Target High Price | 51.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 44.66667 |
| Target Median Price | 45.0 |
| Total Cash | 540,515,008 |
| Total Cash Per Share | 8.755 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.90375 |
| Two Hundred Day Average Change | 3.0962505 |
| Two Hundred Day Average Change Percent | 0.119529046 |
| Type Disp | Equity |
| Volume | 371,723 |
| Website | https://www.damoratx.com |
| Zip | 2,453 |